Inspire Medical Systems Future Growth
Future criteria checks 0/6
Inspire Medical Systems's earnings are forecast to decline at 13.5% per annum while its annual revenue is expected to grow at 4.3% per year. EPS is expected to decline by 17.1% per annum. Return on equity is forecast to be 5.1% in 3 years.
Key information
-13.5%
Earnings growth rate
-17.11%
EPS growth rate
| Medical Equipment earnings growth | 16.1% |
| Revenue growth rate | 4.3% |
| Future return on equity | 5.08% |
| Analyst coverage | Good |
| Last updated | 22 May 2026 |
Recent future growth updates
Recent updates
Seeking Alpha • 12h
Inspire Medical: Golden Opportunity To Monetize A Fundamentally Mispriced Selloff
Summary Inspire Medical Systems faces a sharp revenue slowdown due to temporary CPT coding and CMS Project WISeR disruptions, not fundamental business weakness. INSP maintains a robust balance sheet with ~$400M in liquidity and zero debt, providing downside insulation and supporting a 1x EV/sales valuation at depressed prices. Competitive threats from Nyxoah and GLP-1 therapies are manageable, with IP litigation successes and GLP-1s potentially expanding INSP's addressable market. My cash-secured put strategy at a $25 strike targets a >19% annualized return, monetizing technical uncertainty while maintaining a 40%+ cushion to current prices. Read the full article on Seeking Alpha
Narrative Update • Jun 02
INSP: CMS Coding Progress Will Gradually Support Future Reimbursement And Earnings Power
Analysts have cut the blended price target for Inspire Medical Systems from about $79 to about $52 as they factor in lower assumed revenue growth, more conservative profit margins, and ongoing reimbursement and coding uncertainty highlighted in recent Street research. Analyst Commentary Recent Street research on Inspire Medical Systems clusters around reimbursement mechanics, coding pathways for Inspire V, and how these issues flow through to growth expectations and valuation.
Narrative Update • May 19
INSP: CMS Billing Clarity And Execution On Reset Plan Will Shape Returns
For Inspire Medical Systems, the analyst fair value estimate has been adjusted from $56.00 to $45.00, as analysts factor in revised revenue growth expectations, modestly lower profit margin assumptions, a slightly reduced discount rate, and updated future P/E inputs following recent price target cuts and reimbursement related concerns highlighted in Street research. Analyst Commentary Recent Street research around Inspire Medical Systems has tilted cautious, with several bearish analysts updating their views after reimbursement headlines, guidance changes, and evolving expectations for long term execution.Narrative Update • May 01
INSP: CMS Coding Clarity And Execution On Revised Plan Will Shape Returns
Analysts have trimmed their average price targets on Inspire Medical Systems by single digit dollar amounts, reflecting recent reductions from multiple firms while still assuming revenue growth, profit margin, and P/E inputs that remain largely consistent with prior expectations. Analyst Commentary Recent Street research on Inspire Medical Systems has tilted cautious, with several bearish analysts cutting price targets by single to double digit dollar amounts and, in some cases, lowering ratings.Narrative Update • Apr 17
INSP: CMS Coding Outcomes And Execution Reset Will Shape Future Earnings Power
The analyst fair value estimate for Inspire Medical Systems has moved from $60.00 to $56.00, reflecting broadly lower Street price targets as analysts factor in CMS reimbursement uncertainty and adjust their assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent research has skewed cautious on Inspire Medical Systems as reimbursement questions and revised company guidance filter through analyst models.Narrative Update • Apr 03
INSP: CMS Coding Clarity Will Support Future Reimbursement And Earnings Power
Analysts have reset the fair value estimate for Inspire Medical Systems to $79.42, down from $124.40, as they factor in lower revenue growth assumptions, a slimmer future P/E of 26.47 instead of 45.15, and updated views on reimbursement clarity following recent CMS coding decisions. Analyst Commentary Recent Street research around Inspire Medical Systems has centered on reimbursement clarity, coding changes from CMS and how these factors feed into execution risk and valuation.Narrative Update • Mar 20
INSP: Coding Clarity And Execution Risks Will Shape Reimbursement And Earnings Power
Analysts have trimmed their price targets on Inspire Medical Systems, with one high profile cut from $130 to $60 and another adjustment from $95 to $85. These changes reflect uncertainty around future reimbursement details, even as recent CMS coding updates are viewed as directionally positive and hospital facility fees remain essentially unchanged.
Narrative Update • Mar 06
INSP: New CMS C Codes Will Reshape Pricing Power And Procedure Volumes
The analyst price target for Inspire Medical Systems has been reduced from $180 to about $106, as analysts factor in lower revenue growth assumptions, a different future P/E outlook, and near term uncertainties around guidance and reimbursement coding, even as margin expectations remain relatively stable. Analyst Commentary Recent research commentary around Inspire Medical Systems has centered on two main themes: lower long term growth expectations and ongoing uncertainty around reimbursement coding, offset by pockets of optimism tied to recent coding updates and valuation reset.Narrative Update • Feb 20
INSP: Future Coding Uncertainty And Capacity Constraints Will Temper Reimbursement Tailwinds
Analysts have reset expectations on Inspire Medical Systems, with our fair value estimate moving from $81.00 to $60.00 following a wave of target cuts around Q4 earnings. The change reflects lower revenue growth assumptions, a reduced future P/E multiple, and new uncertainties after the company's FY26 sales guidance update were incorporated into long term models.Analysis Article • Feb 14
Results: Inspire Medical Systems, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Last week, you might have seen that Inspire Medical Systems, Inc. ( NYSE:INSP ) released its full-year result to the...Narrative Update • Feb 06
INSP: Reimbursement Upcodes And Coding Resolution Will Support Long Term Upside
Narrative Update: Inspire Medical Systems Analysts have trimmed their price expectations for Inspire Medical Systems, with our fair value estimate moving from US$140.13 to US$124.40. This reflects lower assumed future P/E multiples and recent target cuts tied to coding and reimbursement uncertainty, partially balanced by prior optimism around CMS reimbursement changes.Narrative Update • Jan 22
INSP: Surprise Medicare Reimbursement Shift Will Reshape Pricing Power And Procedure Volumes
Narrative Update Analysts have trimmed their price target on Inspire Medical Systems to about $180, down from roughly $212, as they temper fair value, revenue growth and margin assumptions while still recognizing support from stronger Medicare reimbursement and improved pricing power. Analyst Commentary Recent research on Inspire Medical Systems has tilted more positive, with several bullish analysts highlighting reimbursement changes, pricing power and easing execution headwinds as key supports for the stock's valuation framework.Analysis Article • Jan 09
Why We're Not Concerned Yet About Inspire Medical Systems, Inc.'s (NYSE:INSP) 32% Share Price Plunge
The Inspire Medical Systems, Inc. ( NYSE:INSP ) share price has softened a substantial 32% over the previous 30 days...Narrative Update • Jan 08
INSP: Future Reimbursement Tailwinds Will Not Resolve Capacity And Execution Risks
Analysts have reduced their fair value estimate for Inspire Medical Systems to $81 from $97, even as they point to a higher expected profit margin and a lower future P/E multiple, supported by recent positive reimbursement changes and greater confidence around pricing and volumes. Analyst Commentary Recent Street research around Inspire Medical Systems has shifted quickly as reimbursement news has come through.Narrative Update • Dec 25
INSP: Surprise Medicare Reimbursement Upcodes Will Support Stronger Long Term Upside
Our analyst price target for Inspire Medical Systems has increased from approximately $128 to $140 per share, as analysts now expect higher sustainable reimbursement driven by surprise Medicare and OPPS upcodes, improved pricing power, and de risked 2026 revenue estimates, despite only modest adjustments to long term growth and margin assumptions. Analyst Commentary Recent Street research on Inspire Medical Systems reflects a meaningful turn in sentiment following the positive Medicare and outpatient reimbursement developments, with several upgrades and target increases offset by lingering concerns around execution and competitive dynamics.Narrative Update • Dec 11
INSP: Medicare Reimbursement Upside Will Offset Ongoing Execution And Competitive Risks
Analysts have raised their fair value estimate for Inspire Medical Systems by about $10 to roughly $128 per share, citing positive surprises in Medicare and commercial reimbursement that are expected to support higher pricing, stronger long term growth, and justify a higher earnings multiple. Analyst Commentary Recent Street research reflects a notable shift in sentiment toward Inspire Medical Systems, with several bullish analysts highlighting the impact of unexpectedly favorable reimbursement decisions and the company’s improving execution, while more cautious voices focus on operational headwinds and valuation risk.Narrative Update • Nov 26
INSP: Persistent Execution Challenges Will Undermine Confidence Despite Medicare Reimbursement Upside
The analyst price target for Inspire Medical Systems has risen significantly. Consensus has moved from approximately $107 to $118, as analysts highlight stronger-than-expected reimbursement gains and an improved long-term outlook for the company's revenue growth and profit margins.Analysis Article • Nov 25
Investors Appear Satisfied With Inspire Medical Systems, Inc.'s (NYSE:INSP) Prospects As Shares Rocket 51%
Inspire Medical Systems, Inc. ( NYSE:INSP ) shares have had a really impressive month, gaining 51% after a shaky period...Narrative Update • Nov 12
INSP: Outperform Ratings And Strong Earnings Will Drive Share Price Recovery
Inspire Medical Systems' average analyst price target was revised down by approximately $10.60 per share. Analysts cited slower expected revenue growth and ongoing operational headwinds as factors impacting near-term performance.Analysis Article • Nov 10
We Think Inspire Medical Systems' (NYSE:INSP) Robust Earnings Are Conservative
Inspire Medical Systems, Inc. ( NYSE:INSP ) recently posted some strong earnings, and the market responded positively...Analysis Article • Nov 06
Inspire Medical Systems, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Shareholders of Inspire Medical Systems, Inc. ( NYSE:INSP ) will be pleased this week, given that the stock price is up...Narrative Update • Oct 29
Sector Dislocations And Transitory Headwinds Will Create Long-Term Upside Opportunity
The average analyst price target for Inspire Medical Systems has been revised downward by nearly $10 to $117.40. Analysts cite persistent sector headwinds, cautious sentiment on revenue growth, and ongoing uncertainty around future guidance as reasons for this adjustment.Narrative Update • Oct 15
Procedure Improvements And Expanding Medicare Access Will Open Future Opportunities
Inspire Medical Systems' analyst price target has decreased from $135.13 to $127.47, as analysts cite near-term headwinds including lowered revenue guidance, increased uncertainty around growth and margins, and cautious sentiment heading into upcoming earnings reports. Analyst Commentary Recent analyst commentary on Inspire Medical Systems highlights a mix of optimism and caution, with valuation targets adjusted and sentiment reflecting both the challenges and the potential opportunities seen in the company's outlook.Narrative Update • Sep 24
Procedure Improvements And Expanding Medicare Access Will Open Future Opportunities
Analysts have cut Inspire Medical Systems’ price target from $144.53 to $135.13 due to heightened downside risks to near-term sales and earnings growth, persistent operational headwinds, lowered management guidance, and slower facility activations. Analyst Commentary Bearish analysts cite elevated downside risks to near-term sales growth and EPS estimates, driven by ongoing headwinds identified in recent earnings calls.Analysis Article • Aug 27
Investors Give Inspire Medical Systems, Inc. (NYSE:INSP) Shares A 29% Hiding
To the annoyance of some shareholders, Inspire Medical Systems, Inc. ( NYSE:INSP ) shares are down a considerable 29...Analysis Article • Aug 07
Earnings Miss: Inspire Medical Systems, Inc. Missed EPS And Analysts Are Revising Their Forecasts
NYSE:INSP 1 Year Share Price vs Fair Value Explore Inspire Medical Systems's Fair Values from the Community and select...Narrative Update • Aug 06
Procedure Improvements And Expanding Medicare Access Will Open Future Opportunities
The sharp reduction in Inspire Medical Systems’ consensus price target from $210.73 to $151.00 reflects a meaningful deterioration in both net profit margin and expected revenue growth. What's in the News Company lowered full-year 2025 revenue guidance to $900–$910 million, down from prior guidance of $940–$955 million.Analysis Article • Jul 08
Investors Interested In Inspire Medical Systems, Inc.'s (NYSE:INSP) Revenues
When you see that almost half of the companies in the Medical Equipment industry in the United States have...Analysis Article • May 25
The Return Trends At Inspire Medical Systems (NYSE:INSP) Look Promising
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Analysis Article • Apr 30
Should You Investigate Inspire Medical Systems, Inc. (NYSE:INSP) At US$160?
Inspire Medical Systems, Inc. ( NYSE:INSP ), might not be a large cap stock, but it saw a decent share price growth of...Analysis Article • Mar 25
Investors Appear Satisfied With Inspire Medical Systems, Inc.'s (NYSE:INSP) Prospects
You may think that with a price-to-sales (or "P/S") ratio of 6.3x Inspire Medical Systems, Inc. ( NYSE:INSP ) is a...Seeking Alpha • Mar 18
Inspire Medical Systems: Fine Company, Stretched Valuations And Slowing Growth
Summary Inspire Medical Systems, Inc. posted strong Q4 results in February with impressive revenue and profit growth, and is launching the new version of its flagship product in 2025. The company currently enjoys mostly positive analyst firm coverage and possesses a rock-solid balance sheet. Inspire should also see few impacts from changes in tariff policies. However, revenue growth is projected to slow as the company grows off of a larger base and valuations seem more than stretched at current trading levels. An updated analysis around INSP stock follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • Mar 07
Inspire Medical Systems, Inc.'s (NYSE:INSP) Intrinsic Value Is Potentially 31% Above Its Share Price
Key Insights Inspire Medical Systems' estimated fair value is US$229 based on 2 Stage Free Cash Flow to Equity Current...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 954 | 61 | 118 | 168 | 10 |
| 12/31/2027 | 876 | 36 | 168 | 194 | 15 |
| 12/31/2026 | 843 | 15 | 118 | 176 | 15 |
| 3/31/2026 | 915 | 131 | 97 | 137 | N/A |
| 12/31/2025 | 912 | 145 | 78 | 117 | N/A |
| 9/30/2025 | 883 | 45 | 99 | 134 | N/A |
| 6/30/2025 | 861 | 53 | 85 | 117 | N/A |
| 3/31/2025 | 840 | 67 | 79 | 115 | N/A |
| 12/31/2024 | 803 | 54 | 91 | 130 | N/A |
| 9/30/2024 | 756 | 33 | 38 | 78 | N/A |
| 6/30/2024 | 706 | 6 | -9 | 30 | N/A |
| 3/31/2024 | 661 | -16 | 3 | 35 | N/A |
| 12/31/2023 | 625 | -21 | 1 | 25 | N/A |
| 9/30/2023 | 570 | -33 | 8 | 27 | N/A |
| 6/30/2023 | 526 | -41 | 19 | 34 | N/A |
| 3/31/2023 | 466 | -44 | 11 | 23 | N/A |
| 12/31/2022 | 408 | -45 | 2 | 12 | N/A |
| 9/30/2022 | 348 | -50 | -14 | -7 | N/A |
| 6/30/2022 | 301 | -44 | -23 | -18 | N/A |
| 3/31/2022 | 262 | -43 | -27 | -22 | N/A |
| 12/31/2021 | 233 | -42 | -25 | -20 | N/A |
| 9/30/2021 | 201 | -47 | -30 | -25 | N/A |
| 6/30/2021 | 175 | -47 | -38 | -34 | N/A |
| 3/31/2021 | 134 | -57 | -52 | -49 | N/A |
| 12/31/2020 | 115 | -57 | -55 | -53 | N/A |
| 9/30/2020 | 96 | -59 | -57 | -55 | N/A |
| 6/30/2020 | 81 | -57 | -51 | -49 | N/A |
| 3/31/2020 | 87 | -41 | -39 | -37 | N/A |
| 12/31/2019 | 82 | -33 | N/A | -33 | N/A |
| 9/30/2019 | 72 | -29 | N/A | -29 | N/A |
| 6/30/2019 | 64 | -25 | N/A | -30 | N/A |
| 3/31/2019 | 57 | -24 | N/A | -23 | N/A |
| 12/31/2018 | 51 | -22 | N/A | -19 | N/A |
| 9/30/2018 | 44 | -21 | N/A | -19 | N/A |
| 6/30/2018 | 38 | -21 | N/A | -19 | N/A |
| 3/31/2018 | 33 | -20 | N/A | -17 | N/A |
| 12/31/2017 | 29 | -18 | N/A | -16 | N/A |
| 12/31/2016 | 16 | -19 | N/A | -18 | N/A |
| 12/31/2015 | 8 | -21 | N/A | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INSP's earnings are forecast to decline over the next 3 years (-13.5% per year).
Earnings vs Market: INSP's earnings are forecast to decline over the next 3 years (-13.5% per year).
High Growth Earnings: INSP's earnings are forecast to decline over the next 3 years.
Revenue vs Market: INSP's revenue (4.3% per year) is forecast to grow slower than the US market (11.8% per year).
High Growth Revenue: INSP's revenue (4.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INSP's Return on Equity is forecast to be low in 3 years time (5.1%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/08 21:52 |
| End of Day Share Price | 2026/06/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inspire Medical Systems, Inc. is covered by 24 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Ravi Misra | Berenberg |
| Travis Steed | BofA Global Research |